Mitochondria in the etiology of Parkinson's disease

Handbook of Clinical Neurology

Volumn 83, Issue , 2007, Pages

  Schapira, Anthony H V ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649319285     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)83022-3     Document Type: Review

References (109)

1. Benaroudj N., Zwickl P., Seemuller E., et al. ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol Cell 11 1 (2003) 69-78
2. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 5521 (2001) 1552-1555
3. Benecke R., Strumper P., and Weiss H. Electron transfer complex I defect in idiopathic dystonia. Ann Neurol 32 5 (1992) 683-686
4. Betarbet R., Sherer T.B., MacKenzie G., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 12 (2000) 1301-1306
5. Bodnar A.G., Cooper J.M., Holt I.J., et al. Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion. Am J Hum Genet 53 3 (1993) 663-669
6. Bykova N.V., Egsgaard H., and Moller I.M. Identification of 14 new phosphoproteins involved in important plant mitochondrial processes. FEBS Lett 540 1-3 (2003) 141-146
7. Calne D.B., Langston J.W., Martin W.R., et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 317 6034 (1985) 246-248
8. Ceballos I., Lafon M., Javoy-Agid F., et al. Superoxide dismutase and Parkinson's disease. Lancet 335 8696 (1990) 1035-1036
9. Champy P., Hoglinger G.U., Feger J., et al. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J Neurochem 88 1 (2004) 63-69
10. Chen R., Fearnley I.M., Peak-Chew S.Y., et al. The phosphorylation of subunits of complex I from bovine heart mitochondria. J Biol Chem 279 25 (2004) 26036-26045
11. Chiba K., Trevor A.J., and Castagnoli Jr. N. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 128 3 (1985) 1228-1232
12. Cock H.R., Tabrizi S.J., Cooper J.M., et al. The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy. Ann Neurol 44 2 (1998) 187-193
13. Cohen P. The origins of protein phosphorylation. Nat Cell Biol 4 5 (2002) E127-E130
14. Cooper J.M., Daniel S.E., Marsden C.D., et al. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. Mov Disord 10 3 (1995) 295-297
15. D'Amato R.J., Benham D.F., and Snyder S.H. Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin. J Neurochem 48 2 (1987) 653-658
16. Darios F., Corti O., Lucking C.B., et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12 5 (2003) 517-526
17. Davis G.C., Williams A.C., Markey S.P., et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1 3 (1979) 249-254
18. De Vries D.D., Went L.N., Bruyn G.W., et al. Genetic and biochemical impairment of mitochondrial complex I activity in a family with Leber hereditary optic neuropathy and hereditary spastic dystonia. Am J Hum Genet 58 4 (1996) 703-711
19. Dexter D., Carter C., Agid F., et al. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet 2 8507 (1986) 639-640
20. Di Monte D.A., Wu E.Y., Irwin I., et al. Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes. Glia 5 1 (1992) 48-55
21. Dunbar D.R., Moonie P.A., Zeviani M., et al. Complex I deficiency is associated with 3243G:C mitochondrial DNA in osteosarcoma cell cybrids. Hum Mol Genet 5 1 (1996) 123-129
22. Forno L.S., Langston J.W., Delanney L.E., et al. An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res 448 1 (1988) 150-157
23. Giasson B.I., Duda J.E., Murray I.V., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 5493 (2000) 985-989
24. Goldberg M.S., Fleming S.M., Palacino J.J., et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278 44 (2003) 43628-43635
25. Good P.F., Hsu A., Werner P., et al. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57 4 (1998) 338-342
26. Gordon E.B. Carbon-monoxide encephalopathy. Br Med J 5444 (1965) 1232
27. Greene J.C., Whitworth A.J., Kuo I., et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 100 7 (2003) 4078-4083
28. Grinker R.R. Parkinsonism following carbon monoxide poisoning. J Nerv Ment Dis 64 (1926) 18-28
29. Gu M., Gash M.T., Cooper J.M., et al. Mitochondrial respiratory chain function in multiple system atrophy. Mov Disord 12 3 (1997) 418-422
30. Gu M., Cooper J.M., Taanman J.W., et al. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 44 2 (1998) 177-186
31. Haas R.H., Nasirian F., Nakano K., et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37 6 (1995) 714-722
32. Hantraye P., Brouillet E., Ferrante R., et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 2 9 (1996) 1017-1021
33. Hatano Y., Li Y., Sato K., et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 56 3 (2004) 424-427
34. Hirsch E.C., Graybiel A.M., and Agid Y. Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease. Acta Neurol Scand Suppl 126 (1989) 19-22
35. Hoglinger G.U., Carrard G., Michel P.P., et al. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 86 5 (2003) 1297-1307
36. Hoglinger G.U., Feger J., Prigent A., et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84 3 (2003) 491-502
37. Hojlund K., Wrzesinski K., Larsen P.M., et al. Proteome analysis reveals phosphorylation of ATP synthase beta-subunit in human skeletal muscle and proteins with potential roles in type 2 diabetes. J Biol Chem 278 12 (2003) 10436-10442
38. Huang C.C., Lu C.S., Chu N.S., et al. Progression after chronic manganese exposure. Neurology 43 8 (1993) 1479-1483
39. Hunter T. Signaling-2000 and beyond. Cell 100 1 (2000) 113-127
40. Ikebe S., Tanaka M., Ohno K., et al. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 170 3 (1990) 1044-1048
41. Ikebe S., Tanaka M., and Ozawa T. Point mutations of mitochondrial genome in Parkinson's disease. Brain Res Mol Brain Res 28 2 (1995) 281-295
42. Itzhak Y., and Ali S.F. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem 67 4 (1996) 1770-1773
43. Javitch J.A., and Snyder S.H. Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 106 2 (1984) 455-456
44. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand Suppl 136 (1991) 6-15
45. Jun A.S., Brown M.D., and Wallace D.C. A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. Proc Natl Acad Sci USA 91 13 (1994) 6206-6210
46. Kish S.J., Morito C., and Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 58 3 (1985) 343-346
47. Klawans H.L., Stein R.W., Tanner C.M., et al. A pure parkinsonian syndrome following acute carbon monoxide intoxication. Arch Neurol 39 5 (1982) 302-304
48. Kosel S., Grasbon-Frodl E.M., Hagenah J.M., et al. Parkinson disease: analysis of mitochondrial DNA in monozygotic twins. Neurogenetics 2 4 (2000) 227-230
49. Krige D., Carroll M.T., Cooper J.M., et al. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 32 6 (1992) 782-788
50. Kuiper M.A., Visser J.J., Bergmans P.L., et al. Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. J Neurol Sci 121 1 (1994) 46-49
51. Langston J.W., and Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci 11 1 Suppl (1984) 160-165
52. Langston J.W., Ballard P., Tetrud J.W., et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 4587 (1983) 979-980
53. Lestienne P., Nelson I., Riederer P., et al. Mitochondrial DNA in postmortem brain from patients with Parkinson's disease. J Neurochem 56 5 (1991) 1819
54. Levitt P., Pintar J.E., and Breakefield X.O. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 79 20 (1982) 6385-6389
55. Lucking C.B., Kosel S., Mehraein P., et al. Absence of the mitochondrial A7237T mutation in Parkinson's disease. Biochem Biophys Res Commun 211 2 (1995) 700-704
56. Luoma P., Melberg A., Rinne J.O., et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 364 9437 (2004) 875-882
57. Lyden A., Bondesson U., Larsson B.S., et al. Melanin affinity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, an inducer of chronic parkinsonism in humans. Acta Pharmacol Toxicol (Copenh) 53 5 (1983) 429-432
58. Mancuso M., Filosto M., Oh S.J., et al. A novel polymerase gamma mutation in a family with ophthalmoplegia, neuropathy, and Parkinsonism. Arch Neurol 61 11 (2004) 1777-1779
59. Mann V.M., Cooper J.M., Daniel S.E., et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 36 6 (1994) 876-881
60. Manning G., Whyte D.B., Martinez R., et al. The protein kinase complement of the human genome. Science 298 5600 (2002) 1912-1934
61. Martin W.R.W., Stoessel A.J., and Adam M.J. Imaging of dopamine systems in human subjects exposed to MPTP. In: Markey S.P., Castagnoli Jr. N., Trevor A.J., and Kopin I.J. (Eds). MPTP: A Neurotoxin Producing Parkinsonian Syndrome (1986), Academic Press, New York 315-325
62. Marttila R.J., Lorentz H., and Rinne U.K. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86 2-3 (1988) 321-331
63. McNaught K.S., and Olanow C.W. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 53 Suppl 3 (2003) S73-S84
64. McNaught K.S., Belizaire R., Isacson O., et al. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179 1 (2003) 38-46
65. McNaught K.S., Perl D.P., Brownell A.L., et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56 1 (2004) 149-162
66. Melamed E., Rosenthal J., Globus M., et al. Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA. Brain Res 342 2 (1985) 401-404
67. Mena I. Manganese poisoning. In: Vinken P.J., and Bruyn G.W. (Eds). Handbook of Clinical Neurology. Intoxications of the Nervous System, part I Vol. 36 (1979), North Holland, Amsterdam 217-237
68. Molina J.A., Jimenez-Jimenez F.J., Navarro J.A., et al. Plasma levels of nitrates in patients with Parkinson's disease. J Neurol Sci 127 1 (1994) 87-89
69. Murray J., Marusich M.F., Capaldi R.A., et al. Focused proteomics: monoclonal antibody-based isolation of the oxidative phosphorylation machinery and detection of phosphoproteins using a fluorescent phosphoprotein gel stain. Electrophoresis 25 15 (2004) 2520-2525
70. Ozawa T., Tanaka M., Ino H., et al. Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease. Biochem Biophys Res Commun 176 2 (1991) 938-946
71. Palacino J.J., Sagi D., Goldberg M.S., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279 18 (2004) 18614-18622
72. Parker Jr. W.D., Boyson S.J., and Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26 6 (1989) 719-723
73. Penn A.M., Roberts T., Hodder J., et al. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 45 11 (1995) 2097-2099
74. Perry T.L., Godin D.V., and Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci Lett 33 3 (1982) 305-310
75. Pickart C.M. Mechanisms underlying ubiquitination. Annu Rev Biochem 70 (2001) 503-533
76. Pyle A., Foltynie T., Tiangyou W., et al. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol 57 4 (2005) 564-567
77. Qureshi G.A., Baig S., Bednar I., et al. Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Neuroreport 6 12 (1995) 1642-1644
78. Richter G., Sonnenschein A., Grunewald T., et al. Novel mitochondrial DNA mutations in Parkinson's disease. J Neural Transm 109 5-6 (2002) 721-729
79. Riederer P., and Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38 3-4 (1976) 277-301
80. Rohe C.F., Montagna P., Breedveld G., et al. Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism. Ann Neurol 56 3 (2004) 427-431
81. Ross O.A., McCormack R., Maxwell L.D., et al. mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish. Exp Gerontol 38 4 (2003) 397-405
82. Saggu H., Cooksey J., Dexter D., et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53 3 (1989) 692-697
83. Sanchez-Ramos J., Övervik E., and Ames B.N. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3 (1994) 197-204
84. Schapira A.H. Evidence for mitochondrial dysfunction in Parkinson's disease-a critical appraisal. Mov Disord 9 2 (1994) 125-138
85. Schapira A.H., Cooper J.M., Dexter D., et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 8649 (1989) 1269
86. Schapira A., Cooper J.M., and Dexter D. Mitochondrial complex I deficiency in Parkinson's disease. Ann Neurol 26 (1989) 122-123
87. Schapira A.H., Holt I.J., Sweeney M., et al. Mitochondrial DNA analysis in Parkinson's disease. Mov Disord 5 4 (1990) 294-297
88. Schapira A.H., Mann V.M., Cooper J.M., et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55 6 (1990) 2142-2145
89. Schapira A.H., Warner T., Gash M.T., et al. Complex I function in familial and sporadic dystonia. Ann Neurol 41 4 (1997) 556-559
90. Schulenberg B., Aggeler R., Beechem J.M., et al. Analysis of steady-state protein phosphorylation in mitochondria using a novel fluorescent phosphosensor dye. J Biol Chem 278 29 (2003) 27251-27255
91. Schulenberg B., Goodman T.N., Aggeler R., et al. Characterization of dynamic and steady-state protein phosphorylation using a fluorescent phosphoprotein gel stain and mass spectrometry. Electrophoresis 25 15 (2004) 2526-2532
92. Schultz W., Scarnati E., Sundstrom E., et al. Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by the catecholamine uptake inhibitor nomifensine: behavioral analysis in monkeys with partial striatal dopamine depletions. Neuroscience 31 1 (1989) 219-230
93. Schwartz M., and Vissing J. Paternal inheritance of mitochondrial DNA. N Engl J Med 347 8 (2002) 576-580
94. Shen J., and Cookson M.R. Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 43 3 (2004) 301-304
95. Sherman M.Y., and Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29 1 (2001) 15-32
96. Shoffner J.M., Brown M.D., Torroni A., et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 17 1 (1993) 171-184
97. Sian J., Dexter D.T., Lees A.J., et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36 3 (1994) 348-355
98. Singer T.P., Salach J.I., Castagnoli Jr. N., et al. Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine with monoamine oxidases. Biochem J 235 3 (1986) 785-789
99. Swerdlow R.H., Parks J.K., Miller S.W., et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40 4 (1996) 663-671
100. Taylor D.J., Krige D., Barnes P.R., et al. A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease. J Neurol Sci 125 1 (1994) 77-81
101. Tetrud J.W., and Langston J.W. Tremor in MPTP-induced parkinsonism. Neurology 42 2 (1992) 407-410
102. Thyagarajan D., Bressman S., Bruno C., et al. A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann Neurol 48 5 (2000) 730-736
103. Truong D.D., Harding A.E., Scaravilli F., et al. Movement disorders in mitochondrial myopathies. A study of nine cases with two autopsy studies. Mov Disord 5 2 (1990) 109-117
104. Unoki M., and Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20 33 (2001) 4457-4465
105. Valente E.M., Abou-Sleiman P.M., Caputo V., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 5674 (2004) 1158-1160
106. Valente E.M., Salvi S., Ialongo T., et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 56 3 (2004) 336-341
107. van der Walt J.M., Nicodemus K.K., Martin E.R., et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 72 4 (2003) 804-811
108. Vives-Bauza C., Andreu A.L., Manfredi G., et al. Sequence analysis of the entire mitochondrial genome in Parkinson's disease. Biochem Biophys Res Commun 290 5 (2002) 1593-1601
109. Voges D., Zwickl P., and Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68 (1999) 1015-1068